June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Systemic Pharmacodynamic Efficacy of a Complement Factor B Antisense Oligonucleotide in Preclinical and Phase 1 Clinical Studies
Author Affiliations & Notes
  • Michael McCaleb
    Ionis Pharmaceuticals, Carlsbad, California, United States
  • Tamar R Grossman
    Ionis Pharmaceuticals, Carlsbad, California, United States
  • Peter Adamson
    GlaxoSmithKline, Stevenage, United Kingdom
  • Scott Henry
    Ionis Pharmaceuticals, Carlsbad, California, United States
  • Richard S Geary
    Ionis Pharmaceuticals, Carlsbad, California, United States
  • Steve G Hughes
    Ionis Pharmaceuticals, Carlsbad, California, United States
  • Brett P Monia
    Ionis Pharmaceuticals, Carlsbad, California, United States
  • Footnotes
    Commercial Relationships   Michael McCaleb, Ionis Pharmaceuticals (E); Tamar Grossman, Ionis Pharmaceuticals (E); Peter Adamson, None; Scott Henry, Ionis Pharmaceuticals (E); Richard Geary, Ionis Pharmaceuticals (E); Steve Hughes, Ionis Pharmaceuticals (E); Brett Monia, Ionis Pharmaceuticals (E)
  • Footnotes
    Support  Ionis Pharmaceuticals
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1952. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michael McCaleb, Tamar R Grossman, Peter Adamson, Scott Henry, Richard S Geary, Steve G Hughes, Brett P Monia; Systemic Pharmacodynamic Efficacy of a Complement Factor B Antisense Oligonucleotide in Preclinical and Phase 1 Clinical Studies. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1952.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Over-activation of the alternative pathway (AP) of complement system may have a role in the development of geographic atrophy (GA) secondary to AMD. Complement factor B (FB), a pivotal fluid-phase component of AP, is produced predominately in the liver and circulates at high levels throughout the vascular system. To diminish AP activity in the choriocapillaris, we have identified a highly specific and efficacious antisense oligonucleotide (ASO) targeting the human CFB gene to reduce circulating levels of FB protein.

Methods : HepG2 cells were used to screen second generation MOE gapmer ASO for reduction of FB mRNA levels. In vivo efficacy of ASO was demonstrated in humanized FB transgenic mice (hTg). Clinical safety, pharmacokinetic (PK) and pharmacodynamic (PD) activity were evaluated in a Phase 1, masked, placebo-controlled single and multiple ascending dose studies (SAD and MAD) in healthy volunteers.

Results : The FB ASO had an in vitro IC50 of 0.18 uM in HepG2 cells and in vivo EC50 of 4.52 mg/kg/wk in FB hTg mice. In vivo targeting of the ASO to hepatocytes was dramatically augmented by conjugation to a GalNAc moiety, resulting in a lowering of the EC50 in FB hTg mice to 0.52 mg/kg/wk. In a Phase 1, SAD study, IONIS-FB-LRX reduced plasma FB levels dose dependently by approximately 50%, 34% and 11% at 30 days after a single, subcutaneous, administration of 40 mg (~0.6 mg/kg), 20 and 10 mg, respectively. The 50% reduction of FB levels was accompanied by similar reductions of FB function and Bb, without meaningful changes of AH50, CH50, C3 or factor D (mean +/- SE % reductions of -49+/-3, -33+/-5, -55+/-6, - 6+/-9, 15+/-9, -11+/-15 and -6+/-5%, respectively). No drug-related adverse events were reported during the Ph 1 SAD study. In addition, PKPD modeling indicates response durability suitable for weekly or monthly dosing. Multiple dose administration of IONIS-FB-LRX during a six week period provided greater reductions in circulating FB levels.

Conclusions : In summary, a novel antisense oligonucleotide targeting complement factor B, IONIS-FB-LRX, effectively reduces circulating levels of FB, with a potential to diminish over-activity of the alternative complement pathway in the choriocapillaris of patients having GA associated with AMD. The safety profile of IONIS-FB-LRX supports further development.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×